Florian Lang

USPTO Granted Patents = 13 (Patent Applications = 2)

CIPO Patents = 3

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 41(Granted Patents)

Location History:

Tübingen, DE (2008 - 2009)
Tuebingen, DE (2006 - 2014)

Company Filing History:

Eberhard-karls-universitaet Tuebingen Universitaetsklinikum

patents

1 out of 121

Merck Patent Gesellschaft

patents

4. 1 out of 1,248

Merck Patent Gesellschaft MIT Beschrankter Haftung

patents

Years Active: 2006-2014

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8815924 - Heterocyclic carbonyl compounds (2014-08-26),

2. 8546613 - SGK1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas (2013-10-01),

3. 8492440 - Difluorophenyldiacylhydrazide derivatives (2013-07-23),

4. 8377975 - Oxadiazole derivatives for the treatment of diabetes (2013-02-19),

5. 8207210 - Aminoindazolylurea derivatives (2012-06-26),

6. 7884126 - Indazole-heteroaryl derivatives (2011-02-08),

7. 7872039 - 3-aminoindazoles (2011-01-18),

8. 7776920 - Mandelic hydrazides (2010-08-17),

9. 7767716 - Acyl hydrazines as kinase inhibitors, in particular for SGK (2010-08-03),

10. 7619115 - Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides (2009-11-17),

11. 7405239 - Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction (2008-07-29),

12. 7235364 - CICKb mutation as a diagnostic and therapeutical target (2007-06-26),

13. 7074573 - CLCKb mutation as a diagnostic therapeutical target (2006-07-11),

Title: Florian Lang: Innovator in Heterocyclic Compounds

Introduction

Florian Lang is a prominent inventor based in Tuebingen, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of heterocyclic compounds. With a total of 13 patents to his name, Lang's work focuses on innovative solutions for various health conditions.

Latest Patents

Lang's latest patents include novel heterocyclic carbonyl compounds that serve as SGK inhibitors. These compounds can be utilized in the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases, and kidney diseases. Additionally, he has developed SGK1 inhibitors aimed at the prophylaxis and therapy of viral diseases and carcinomas, showcasing his commitment to addressing critical health challenges.

Career Highlights

Throughout his career, Florian Lang has worked with notable organizations, including Merck Patent GmbH and Eberhard Karls University Tuebingen University Hospital. His experience in these institutions has allowed him to refine his expertise and contribute to groundbreaking research in his field.

Collaborations

Lang has collaborated with esteemed colleagues such as Norbert Beier and Rolf Gericke. These partnerships have further enhanced his research capabilities and have led to the successful development of his patented innovations.

Conclusion

Florian Lang's contributions to the field of medicinal chemistry through his innovative patents highlight his role as a key inventor in the development of treatments for various diseases. His work continues to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.